Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$240.5M
79M shares
52-week range
$2.87 – $10.52
2% from low
Sector
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Exchange
NASDAQ
CS
P/S (TTM)
1.9
EV / FCF (TTM)
32.3
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
www.niagenbioscience.comNo one on the platform currently holds NAGE.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,328,843 | $5.9M |
| Execution date | Ratio |
|---|---|
| 2006-12-07 | 3.1887751-for-1 |
No one on the platform has traded NAGE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 93.8% | — | — | — | ||
| Rev. Growth % | 29.9% | 16.9% | ||||
| Profit Margin % | 13.4% | -9.4% | -32.3% | |||
| Free Cash Flow Margin % | 10.2% | -5.5% | -23.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +17.5% on the P/E track.
At today's price, your expected annual return is +23.2% on the P/E track.
At today's price, your expected annual return is +28.3% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $134M | +5.4% | $0.14 | $0.10–$0.18 | 20.8× | 3 |
| 2027 | $155M | +15.8% | $0.15 | $0.11–$0.21 | 19.4× | 2 |
| 2028 | $182M | +17.4% | $0.25 | $0.24–$0.26 | 12.0× | 2 |
| 2029 | $210M | +15.0% | $0.34 | $0.33–$0.35 | 8.8× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $0.01 | $0.01 | +20.0% |
| 2026-05-06 | $0.06 | $0.07 | +16.7% |
| 2026-03-04 | $0.02 | $0.03 | +50.0% |
| 2025-11-04 | $0.01 | $0.05 | +233.3% |
| 2025-08-06 | $0.02 | $0.04 | +100.0% |
| 2025-05-07 | $0.02 | $0.04 | +100.0% |
| 2025-03-04 | $0.02 | $0.09 | +300.0% |
| 2024-10-31 | $0.01 |
| $0.03 |
| +414.0% |
| $359M |
| — |
| OLMAOlema Pharmaceuticals, Inc. | $10.29 | +0.68% | $899M | — |
| PRTAProthena Corporation plc | $8.86 | -0.78% | $464M | — |
Source: Financial Modeling Prep · peers by sector/industry
$NAGE conceivably, they could fund close to the entirety of 4168 development buy rotating their $$ into 6mo T-bills.
View on StockTwits ↗
$NAGE https://www.reddit.com/r/NicotinamideRiboside/s/erRHWQaQJQ
View on StockTwits ↗$NAGE https://reddit.com/r/nicotinamideriboside/wiki/studies
View on StockTwits ↗$NAGE https://investors.niagenbioscience.com/news/news-details/2026/Niagen-Bioscience-to-Present-at-Canaccord-Genuitys-Well-Summit/default.aspx
View on StockTwits ↗$NAGE https://www.reddit.com/r/NicotinamideRiboside/s/FoK2bxKoj7
View on StockTwits ↗
$NAGE mentioned recently that I interviewed a OneSpaWorld representative on a cruise ship about people who got Niagen Plus IVs. He said that it was selling very well on the ship. He said that people getting Niagen Plus IVs often came back to the spa raving about the results, and that they then started taking TruNiagen capsules "when they get home". I regretted not having asked him how he knew that the customers took capsules after they got off the ship. Apparently AI knows: OneSpaWorld tracks and knows that passengers take capsule Niagen after getting Niagen Plus IV infusions through several direct operational and retail channels. 1, 2 Because OneSpaWorld operates the onboard Medi-Spas as a highly optimized business, they do not just track the clinical treatment—they manage the entire consumer pipeline. 1, 2 Here is exactly how they capture this information: 1 Onboard Retail Sales and "Take-Home" Maintenance Kits (CONTINUED)
View on StockTwits ↗$NAGE Just found this Korean skincare company featuring NR. https://ayucell.com/?srsltid=AfmBOopwuvkhcPZ7aT8NA5IiDuTU4fCxZuyHmQh07g4SdKFeP-EQqk_v
View on StockTwits ↗$NAGE "One of the most under valued stocks...." https://www.investing.com/news/company-news/niagen-bioscience-launches-drug-candidate-for-rare-disease-93CH-4781634
View on StockTwits ↗
$NAGE https://investors.niagenbioscience.com/news/news-details/2026/Niagen-Bioscience-to-Present-at-Canaccord-Genuitys-Well-Summit/default.aspx
View on StockTwits ↗$NAGE I don't get this skin care thing. If NR effects all trillions of cells, why do we need a skin care product?
View on StockTwits ↗$NAGE An AI summary of where we are regarding skincare products: which large skincare companies are interested in Niagen? Large skincare conglomerates, most notably The Estée Lauder Companies, have expressed strong interest in securing supply agreements for Niagen. The ingredient's owner, Niagen Bioscience (formerly known as ChromaDex), has heavily prioritized expansion into the multi-billion-dollar global skincare and beauty sectors. This commercial interest is driven by several key developments: 1. Supply Agreements with Conglomerates During recent investor and industry conferences, management revealed that larger skincare companies—including Estée Lauder—are actively looking into commercial supply agreements to incorporate patented Niagen (nicotinamide riboside) into their own product formulations.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.